Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Showing results (231-240 of 365) with videos related to

Pageof 37
Sort By:
Breast Cancer Research and Treatment|August 1, 1990
Preclinical studies with toremifene as an antitumor agentS P Robinson, C J Parker, V C Jordan
Cancer Research|February 1, 1989
Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growthE M Cormier, M F Wolf, V C Jordan
Breast Cancer Research and Treatment|January 1, 1993
A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogensS Y Jiang, C J Parker, V C Jordan
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1997
Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapyV C Jordan, J I MacGregor, D A Tonetti
Cancer Research|December 1, 1992
Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferationM H Jeng, C J Parker, V C Jordan
The Cancer Journal From Scientific American|May 1, 1996
Should adjuvant tamoxifen therapy be stopped at 5 years?M M Bilimoria, V J Assikis, V C Jordan
Molecular Endocrinology (Baltimore, Md.)|August 1, 1995
A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analogW H Catherino, D M Wolf, V C Jordan
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1997
Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapyV C Jordan, J I MacGregor, D A Tonetti
British Journal of Pharmacology|June 1, 1973
Anti-oestrogenic activity in compounds related to ethamoxytriphetol (MER 25), clomiphene and MRL 37E R Clark, J G Evans, V C Jordan
Cancer Research|November 15, 1990
Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditionsC S Murphy, J J Pink, V C Jordan
Pageof 37

Showing results (231-240 of 365) with videos related to

Sort By:
Pageof 37
Breast Cancer Research and Treatment|August 1, 1990
Preclinical studies with toremifene as an antitumor agentS P Robinson, C J Parker, V C Jordan
Cancer Research|February 1, 1989
Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growthE M Cormier, M F Wolf, V C Jordan
Breast Cancer Research and Treatment|January 1, 1993
A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogensS Y Jiang, C J Parker, V C Jordan
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1997
Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapyV C Jordan, J I MacGregor, D A Tonetti
Cancer Research|December 1, 1992
Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferationM H Jeng, C J Parker, V C Jordan
The Cancer Journal From Scientific American|May 1, 1996
Should adjuvant tamoxifen therapy be stopped at 5 years?M M Bilimoria, V J Assikis, V C Jordan
Molecular Endocrinology (Baltimore, Md.)|August 1, 1995
A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analogW H Catherino, D M Wolf, V C Jordan
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1997
Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapyV C Jordan, J I MacGregor, D A Tonetti
British Journal of Pharmacology|June 1, 1973
Anti-oestrogenic activity in compounds related to ethamoxytriphetol (MER 25), clomiphene and MRL 37E R Clark, J G Evans, V C Jordan
Cancer Research|November 15, 1990
Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditionsC S Murphy, J J Pink, V C Jordan
Pageof 37